Custom service

Transmembrane Proteins Antibody Production

Antibodies against targets that cannot be purified in a native state.

Targets: GPCR, ion channel — transporters, tetraspaninsAntigen formats: DNA, cells, VLP — nanodisc, proteoliposomeTimeline: 14–20 weeks — including FACS screening

A GPCR without its membrane is a partially unfolded protein, and an antibody raised against the unfolded form usually fails on the cell surface. Transmembrane proteins therefore need a different immunisation logic: present the antigen in a lipid environment, or let the animal express it in situ from a DNA construct, and screen on intact cells so that only conformation-sensitive binders survive.

Four antigen formats cover most cases. DNA immunisation with a codon-optimised construct expressing the target on host cells; whole cells overexpressing the protein, fixed or live; virus-like particles carrying the target in a native lipid bilayer; and reconstituted protein in nanodiscs or proteoliposomes for targets that can be purified at all. Each has a bias — DNA favours linear and transiently exposed epitopes, while nanodiscs and VLPs preserve extracellular loops well but require the protein to be expressed and assembled first.

Screening is where these campaigns succeed or fail. Every positive is tested by flow cytometry on cells expressing the target and on the parental line, then against a close homologue if one exists. An antibody that binds only the ELISA plate is not an anti-GPCR antibody, and the screening panel is designed to eliminate it before subcloning.

Service Highlights

Where it fits

This is the route for therapeutic targets that are only meaningful at the cell surface: GPCRs, ion channels, and receptors whose function depends on membrane context. It is also the right approach for anti-CCR5, anti-TIM-3 or anti-CD20-type reagents where the epitope must be extracellular and the antibody must not require detergents to bind.

It is not the route for a target that has a well-behaved soluble ectodomain — purifying that domain and immunising with it is faster and more predictable. Nor is it suitable when no expression system for the target exists and none can be built within the project timeline.

Documentation and QC

Screening data are reported per plate with target-to-parental signal ratios. Each clone is delivered with flow cytometry confirmation on the expressing line, a homologue cross-reactivity panel, and where available a functional readout. Construct sequences and cell line passage numbers are included so that the assay can be reproduced.

Frequently asked questions

Do we need to provide a stable cell line?

It helps, but it is not required. We routinely generate a transient or stable expression line for immunisation and screening, and the construct can be built from your sequence.

How do you prove the antibody binds the native receptor?

By flow cytometry on intact, non-permeabilised cells, compared with the parental line. Binding that disappears after permeabilisation or that requires detergent is not surface binding, and we report it as such.

Can you generate an antibody that modulates receptor function?

Yes, when a functional assay is available. Agonist and antagonist activity is tested after cloning, and the proportion of functional clones among binders varies enormously by target — for some receptors it is one in fifty.

Send the target sequence and any expression construct you already have. We will confirm whether a native-format antigen can be produced, since that decision determines the whole campaign.

Service Highlights

  • Conformation-aware immunisation. DNA, cell-based, VLP or nanodisc formats selected according to the target and whether an expression system exists.
  • FACS as primary screen. Intact cells expressing the target versus parental cells, so only surface-binding clones advance.
  • Homologue counter-screen. Related receptors or channel subtypes included to eliminate family-wide binders that would fail as tools.
  • Epitope class documentation. Binders are classified as recognising extracellular loops, the N-terminus, or a conformational epitope, using peptide and mutant panels.
  • Functional screening. Where a signalling assay exists — cAMP, calcium flux, patch clamp — clones are tested for agonist or antagonist activity.
  • Recombinant rescue. Positive clones are sequenced and reformatted, so a hybridoma that loses expression can still yield an antibody.

How the work runs

  1. Target and format selection

    Expression level, topology and available constructs are reviewed. Where no stable cell line exists, one is generated before immunisation begins.

  2. Antigen preparation

    DNA construct in an expression vector, VLP carrying the target, or protein reconstituted into nanodiscs. Surface expression is confirmed by flow before the first injection.

  3. Immunisation

    DNA prime with electroporation or gene gun, or protein/VLP in adjuvant; boosted at three-week intervals with alternating formats to broaden the response.

  4. Cell-based screening

    Supernatants tested by flow on target-expressing and parental cells, with a ratio cut-off rather than a raw signal cut-off.

  5. Specificity and epitope classification

    Homologue panel, chimeric receptors and peptide competition used to place the epitope and to remove non-specific binders.

  6. Cloning and functional testing

    Subcloning, isotyping, then functional assay — ligand binding, signalling or electrophysiology — according to the target class.

Specifications & timeline

Targets
GPCR, ion channel — transporters, tetraspanins
Antigen formats
DNA, cells, VLP — nanodisc, proteoliposome
Timeline
14–20 weeks — including FACS screening
Target classes
GPCRs, ion channels, transporters, tetraspanins, single-pass receptors
Antigen formats
DNA, whole cells, VLP, nanodisc, proteoliposome, detergent-solubilised protein
Timeline
14–20 weeks, including cell line preparation and FACS screening
Screening
Flow cytometry on live or fixed cells, with parental-cell and homologue controls
Functional assays
cAMP, calcium mobilisation, β-arrestin recruitment, patch clamp, ligand binding
Deliverables
2–5 subcloned hybridomas or recombinant antibodies, FACS data, epitope classification

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.